naltrexone has been researched along with Colorectal Cancer in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, Y; Liu, N; Ma, M; Shan, F; Wang, X | 1 |
| Chen, W; Chen, X; Miao, C; Sun, P; Sun, Z; Wang, J; Weng, M; Wu, Q; Zhu, M | 1 |
| Dalgleish, AG; Dennis, JL; Kaminska, E; Levett, AJ; Liu, WM; Scott, KA | 1 |
| Aung, HH; Li, XL; McEntee, E; Sun, S; Tong, R; Wang, CZ; Xie, JT; Yuan, CS | 1 |
4 other study(ies) available for naltrexone and Colorectal Cancer
| Article | Year |
|---|---|
Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinogenesis; Caspase 3; Cell Differentiation; Colorectal Neoplasms; Cytokines; Disease Progression; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Macrophages; Mice; Mice, Nude; Naltrexone; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Receptors, Opioid; Signal Transduction; Th1 Cells | 2020 |
Nalmefene attenuates malignant potential in colorectal cancer cell via inhibition of opioid receptor.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Movement; Cell Survival; Colorectal Neoplasms; Glycolysis; Mice; Naltrexone; Narcotic Antagonists; Oxygen Consumption; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Opioid; Signal Transduction | 2018 |
Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy.
Topics: Apoptosis Regulatory Proteins; bcl-Associated Death Protein; Colorectal Neoplasms; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Membrane Proteins; Mitochondrial Proteins; Naltrexone; Organoplatinum Compounds; Oxaliplatin | 2016 |
Methylnaltrexone, a peripherally acting opioid receptor antagonist, enhances tumoricidal effects of 5-Fu on human carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Cyclin A; Drug Synergism; Drug Therapy, Combination; Flow Cytometry; Fluorescein-5-isothiocyanate; Fluorouracil; Humans; Lung Neoplasms; Naltrexone; Narcotic Antagonists; Quaternary Ammonium Compounds; Tumor Cells, Cultured | 2009 |